BR0211111A - Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula - Google Patents
Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célulaInfo
- Publication number
- BR0211111A BR0211111A BR0211111-0A BR0211111A BR0211111A BR 0211111 A BR0211111 A BR 0211111A BR 0211111 A BR0211111 A BR 0211111A BR 0211111 A BR0211111 A BR 0211111A
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- engineered rna
- nucleic acid
- transgene
- vector
- Prior art date
Links
- 108020005093 RNA Precursors Proteins 0.000 title abstract 5
- 230000009368 gene silencing by RNA Effects 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 108700019146 Transgenes Proteins 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000009261 transgenic effect Effects 0.000 title abstract 2
- 108020004459 Small interfering RNA Proteins 0.000 abstract 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/02—Cells from transgenic animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
Abstract
"MOLéCULA DE áCIDO NUCLEICO ISOLADA, VETOR, CéLULA HOSPEDEIRA, TRANSGENE, PRECURSOR DE RNA ENGENHEIRADO, ANIMAL TRANSGêNICO NãO HUMANO, E, MéTODO DE INDUZIR A INTERFERêNCIA DE áCIDO RIBONUCLEICO DE UM GENE ALVO EM UMA CéLULA". A invenção fornece precursores de RNA engenheirados que quando expressados em uma célula são processados pela célula para produzir RNAs interferentes pequenos alvejados (siRNAs) que seletivamente silenciam genes alvejados (pela limpeza de mRNAs específicos) usando o caminho de interferência de RNA (RNAi) da própria célula. Introduzindo-se moléculas de ácido nucleico que codificam estes precursores de RNA engenheirados em células in vivo com seq³ências reguladoras apropriadas, a expressão dos precursores de RNA engenheirados pode ser seletivamente controlada tanto temporal quanto espacialmente, isto é, em tempos particulares e/ou em tecidos, órgãos ou células particulares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30518501P | 2001-07-12 | 2001-07-12 | |
PCT/US2002/022010 WO2003006477A1 (en) | 2001-07-12 | 2002-07-12 | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0211111A true BR0211111A (pt) | 2004-06-22 |
Family
ID=23179696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0211111-0A BR0211111A (pt) | 2001-07-12 | 2002-07-12 | Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula |
Country Status (9)
Country | Link |
---|---|
US (8) | US7691995B2 (pt) |
EP (3) | EP1412371B1 (pt) |
JP (1) | JP4210737B2 (pt) |
KR (2) | KR20040022449A (pt) |
BR (1) | BR0211111A (pt) |
CA (2) | CA2921821A1 (pt) |
ES (3) | ES2566561T3 (pt) |
IL (3) | IL159756A0 (pt) |
WO (1) | WO2003006477A1 (pt) |
Families Citing this family (199)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE526406T1 (de) | 1998-03-20 | 2011-10-15 | Commw Scient Ind Res Org | Kontrolle der genexpression |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
EP1147204A1 (en) | 1999-01-28 | 2001-10-24 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US8202846B2 (en) * | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
EP1272630A2 (en) * | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
CA2369944A1 (en) | 2001-01-31 | 2002-07-31 | Nucleonics Inc. | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
ES2566561T3 (es) * | 2001-07-12 | 2016-04-13 | University Of Massachusetts | Producción in vivo de ARN pequeños de interferencia que median el silenciamiento génico |
PT2280070E (pt) | 2001-07-23 | 2015-10-29 | Univ Leland Stanford Junior | Métodos e composições para inibição mediada por iarn da expressão génica em mamíferos |
US10590418B2 (en) | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
WO2003046173A1 (fr) * | 2001-11-28 | 2003-06-05 | Center For Advanced Science And Technology Incubation, Ltd. | Systeme d'expression d'arn si et procede de production de cellules d'inactivation de genes fonctionnelles et analogues au moyen de ce systeme |
GB0130955D0 (en) * | 2001-12-24 | 2002-02-13 | Cancer Res Ventures | Expression system |
DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
EP1483281B2 (en) * | 2002-02-14 | 2012-09-05 | City of Hope | Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules |
AU2003265978A1 (en) | 2002-05-03 | 2003-11-17 | Duke University | A method of regulating gene expression |
US20040023390A1 (en) * | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
US20050042646A1 (en) | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
US20080274989A1 (en) | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
US20040241854A1 (en) | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
US20050106731A1 (en) * | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
WO2004014933A1 (en) | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
AU2002951347A0 (en) * | 2002-09-09 | 2002-09-26 | Benitec Australia Ltd | Genetic silencing |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
US7892793B2 (en) * | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
WO2004047764A2 (en) * | 2002-11-22 | 2004-06-10 | University Of Massachusetts | Modulation of hiv replication by rna interference |
US20060257851A1 (en) * | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
ES2216707B1 (es) * | 2003-04-08 | 2005-12-16 | Josep Maria Aran Perramon | Secuencia oligoribonucleotidica homologa a una region del cdna que codifica para el receptor cd40 humano y oligoribonucleotidos duplex, vectores, composiciones farmaceuticas y usos correspondientes. |
US8609830B2 (en) | 2003-05-16 | 2013-12-17 | Merck Sharp & Dohme Corp. | Methods and compositions for RNA interference |
US20060178327A1 (en) * | 2003-05-30 | 2006-08-10 | Yeung Wah Hin A | Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro |
US8309704B2 (en) * | 2003-06-02 | 2012-11-13 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNAi |
US7750144B2 (en) * | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
DK1633767T3 (en) * | 2003-06-02 | 2019-03-25 | Univ Massachusetts | METHODS AND COMPOSITIONS FOR MANAGING THE EFFECT OF RNA SILENCING |
JP4980716B2 (ja) | 2003-06-12 | 2012-07-18 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 遺伝子サイレンシングに有用な保存されたhbv及びhcv配列 |
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
WO2005047505A2 (en) * | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro rnas |
US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
DK2821085T3 (da) * | 2003-09-12 | 2020-08-03 | Univ Massachusetts | Rna-interferens til behandling af "gain-of-function"-forstyrrelser |
WO2006101474A1 (en) | 2005-03-15 | 2006-09-28 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin k-dependent proteins |
US7480382B2 (en) * | 2003-09-30 | 2009-01-20 | Microsoft Corporation | Image file container |
WO2005035769A2 (en) | 2003-10-09 | 2005-04-21 | E. I. Du Pont De Nemours And Company | Gene silencing by using micro-rna molecules |
ES2344413T3 (es) | 2003-10-14 | 2010-08-26 | Baxter International Inc. | Polipeptido vkorc1 de reciclaje de la vitamina k-epoxido, una diana terapeutica de la cumarina y sus derivados. |
EP1694838A2 (en) * | 2003-10-23 | 2006-08-30 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GPRA AND AAA1 GENE EXPRESSION USING SHORT NUCLEIC ACID (siNA) |
JP4790619B2 (ja) | 2003-10-27 | 2011-10-12 | ロゼッタ インファーマティクス エルエルシー | 遺伝子サイレンシングのためのsiRNAを設計する方法 |
EP1734811A4 (en) * | 2003-11-21 | 2009-03-25 | Revivicor Inc | USE OF INTERFERENCE RNA IN TRANSGENIC ANIMAL PRODUCTION |
US20060134787A1 (en) | 2004-12-22 | 2006-06-22 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA |
US20060069050A1 (en) * | 2004-02-17 | 2006-03-30 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
US20050273868A1 (en) * | 2004-02-17 | 2005-12-08 | University Of Massachusetts | Methods and compositions for enhancing RISC activity in vitro and in vivo |
US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20070265220A1 (en) * | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
JP2008507294A (ja) | 2004-07-26 | 2008-03-13 | ダウ グローバル テクノロジーズ インコーポレイティド | 菌株遺伝子操作による改善されたタンパク質発現のための方法 |
US20060046248A1 (en) * | 2004-08-25 | 2006-03-02 | Avigenics, Inc. | RNA interference in avians |
AU2005276144B2 (en) | 2004-08-26 | 2010-08-05 | The University Of Western Ontario | Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, FN Staphylococcus aureus |
WO2006042328A2 (en) * | 2004-10-12 | 2006-04-20 | John Wayne Cancer Institute | Treatment of cancer and compositions |
CA2583690C (en) | 2004-10-12 | 2016-04-05 | The Rockefeller University | Microrna constructs for the suppression of the expression of targeted genes or the down regulation of targeted genes and methods therefore |
US8148604B2 (en) | 2004-10-21 | 2012-04-03 | Venganza Inc. | Methods and materials for conferring resistance to pests and pathogens of plants |
US8404829B2 (en) * | 2005-01-25 | 2013-03-26 | The Regents Of The University Of California | Predictive and therapeutic markers in ovarian cancer |
KR100694804B1 (ko) | 2005-05-18 | 2007-03-14 | 아주대학교산학협력단 | 작은 헤어핀 rna 분자를 포함하는 자궁 내막암 치료또는 예방용 조성물 및 그를 이용한 자궁 내막암 치료 또는예방 방법 |
US8703769B2 (en) | 2005-07-15 | 2014-04-22 | The University Of North Carolina At Chapel Hill | Use of EGFR inhibitors to prevent or treat obesity |
US20070105803A1 (en) | 2005-08-18 | 2007-05-10 | Muthiah Manoharan | Methods and compositions for treating neurological disease |
EP2980220A1 (en) | 2005-09-20 | 2016-02-03 | BASF Plant Science GmbH | Improved methods controlling gene expression |
KR100877824B1 (ko) | 2005-11-11 | 2009-01-12 | 한국생명공학연구원 | E2epf ucp-vhl 상호작용 및 그 용도 |
US8603991B2 (en) | 2005-11-18 | 2013-12-10 | Gradalis, Inc. | Individualized cancer therapy |
US8916530B2 (en) | 2005-11-18 | 2014-12-23 | Gradalis, Inc. | Individualized cancer therapy |
CN101437933B (zh) | 2005-12-28 | 2013-11-06 | 斯克里普斯研究所 | 作为药物靶标的天然反义和非编码的rna转录物 |
US8758998B2 (en) | 2006-11-09 | 2014-06-24 | Gradalis, Inc. | Construction of bifunctional short hairpin RNA |
US8252526B2 (en) * | 2006-11-09 | 2012-08-28 | Gradalis, Inc. | ShRNA molecules and methods of use thereof |
US8906874B2 (en) | 2006-11-09 | 2014-12-09 | Gradalis, Inc. | Bi-functional shRNA targeting Stathmin 1 and uses thereof |
AU2008218813B2 (en) * | 2007-02-20 | 2014-04-17 | Monsanto Technology, Llc | Invertebrate microRNAs |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
AU2008245696B2 (en) | 2007-04-27 | 2013-11-07 | Pelican Technology Holdings, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
WO2008143774A2 (en) * | 2007-05-01 | 2008-11-27 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
MX2009012568A (es) | 2007-05-22 | 2009-12-08 | Mdrna Inc | Oligonucleotidos de acido ribonucleico sustituidos con hidroximetilo y complejos de acido ribonucleico. |
KR101496803B1 (ko) * | 2007-05-25 | 2015-03-06 | 산토리 홀딩스 가부시키가이샤 | 신규 리소포스파티드산 아실기 전이 효소 유전자 |
EP2581081A3 (en) | 2007-06-01 | 2013-07-31 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
JP5188107B2 (ja) * | 2007-06-21 | 2013-04-24 | 株式会社東芝 | アレイ型受光素子 |
US8183221B2 (en) * | 2007-09-05 | 2012-05-22 | Medtronic, Inc. | Suppression of SCN9A gene expression and/or function for the treatment of pain |
DK2341943T3 (en) * | 2008-09-22 | 2019-02-25 | Dicerna Pharmaceuticals Inc | COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS |
RU2604489C2 (ru) * | 2008-10-03 | 2016-12-10 | КьюРНА,Инк.,US | Лечение заболеваний, связанных с аполипопротеином-а1, путем ингибирования природного антисмыслового транскрипта аполипопротеина-а1 |
KR101610423B1 (ko) | 2008-10-14 | 2016-04-08 | 인비스타 테크놀러지스 에스.에이 알.엘. | 2-sec-알킬-4,5-디-(n-알킬)페놀의 제조 방법 |
CA2744093A1 (en) | 2008-12-03 | 2010-06-10 | Marina Biotech, Inc. | Una oligomer structures for therapeutic agents |
ES2629630T3 (es) | 2008-12-04 | 2017-08-11 | Curna, Inc. | Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO |
MX2011005918A (es) | 2008-12-04 | 2011-06-17 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen. |
US8927511B2 (en) * | 2008-12-04 | 2015-01-06 | Curna, Inc. | Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF |
AU2009336191B2 (en) * | 2008-12-18 | 2017-08-24 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
CA2752237C (en) | 2009-02-12 | 2020-03-24 | Opko Curna, Llc | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
CA2755409C (en) | 2009-03-16 | 2019-04-30 | Joseph Collard | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
CA2755404C (en) | 2009-03-17 | 2020-03-24 | Joseph Collard | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
CA2761142C (en) | 2009-05-06 | 2021-06-08 | Opko Curna, Llc | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
CN103223177B (zh) | 2009-05-06 | 2016-08-10 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
US9012139B2 (en) | 2009-05-08 | 2015-04-21 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family |
CN102575251B (zh) | 2009-05-18 | 2018-12-04 | 库尔纳公司 | 通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病 |
US8895527B2 (en) | 2009-05-22 | 2014-11-25 | Curna, Inc. | Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3 |
CA2764683A1 (en) | 2009-05-28 | 2010-12-02 | Joseph Collard | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
ES2620960T3 (es) | 2009-06-16 | 2017-06-30 | Curna, Inc. | Tratamiento de enfermedades relacionadas con un gen de colágeno mediante la inhibición de un transcrito antisentido natural a un gen de colágeno |
JP6128846B2 (ja) | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療 |
JP6073133B2 (ja) | 2009-06-24 | 2017-02-01 | クルナ・インコーポレーテッド | 腫瘍壊死因子受容体2(tnfr2)に対する天然アンチセンス転写物の抑制によるtnfr2関連疾患の治療 |
WO2010151674A2 (en) | 2009-06-26 | 2010-12-29 | Curna, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
KR101801407B1 (ko) | 2009-07-24 | 2017-11-24 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료 |
KR101802536B1 (ko) | 2009-08-05 | 2017-11-28 | 큐알엔에이, 인크. | 인슐린 유전자 (ins)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ins) 관련된 질환의 치료 |
WO2011019815A2 (en) | 2009-08-11 | 2011-02-17 | Curna, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
JP5943836B2 (ja) | 2009-08-21 | 2016-07-05 | カッパーアールエヌエー,インコーポレイテッド | ‘hsp70相互作用タンパク質c末端’(chip)に対する天然アンチセンス転写産物の阻害によるchip関連疾患の治療 |
JP5964232B2 (ja) | 2009-08-25 | 2016-08-03 | カッパーアールエヌエー,インコーポレイテッド | ‘iqモチーフ含有gtpアーゼ活性化タンパク質’(iqgap)に対する天然アンチセンス転写産物の阻害によるiqgap関連疾患の治療 |
JP6175236B2 (ja) | 2009-09-25 | 2017-08-09 | カッパーアールエヌエー,インコーポレイテッド | フィラグリン(flg)の発現および活性の調整によるflg関連疾患の処置 |
DK2513310T3 (en) | 2009-12-16 | 2018-02-05 | Curna Inc | TREATMENT OF DISEASES CONNECTED WITH MEMBRANE-BONDED TRANSCRIPTION FACTOR Peptidase, site 1 (MBTPS1), BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MBTPS1 |
SG181881A1 (en) | 2009-12-23 | 2012-07-30 | Gradalis Inc | Furin-knockdown bi-functional rna |
EP2515947B1 (en) | 2009-12-23 | 2021-10-06 | CuRNA, Inc. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
CA2785258A1 (en) | 2009-12-23 | 2011-06-30 | Gradalis, Inc. | Furin-knockdown and gm-csf-augmented (fang) cancer vaccine |
DK2516648T3 (en) | 2009-12-23 | 2018-02-12 | Curna Inc | TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF |
EP2519634B1 (en) | 2009-12-29 | 2016-06-01 | CuRNA, Inc. | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 |
JP5993744B2 (ja) | 2009-12-29 | 2016-09-14 | カッパーアールエヌエー,インコーポレイテッド | 核呼吸因子1(nrf1)に対する天然アンチセンス転写物の阻害による核呼吸因子1関連疾患の治療 |
US20120289583A1 (en) | 2009-12-31 | 2012-11-15 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
EP2521784B1 (en) | 2010-01-04 | 2017-12-06 | CuRNA, Inc. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
ES2664866T3 (es) | 2010-01-11 | 2018-04-23 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg |
DK2529015T3 (en) | 2010-01-25 | 2018-02-26 | Curna Inc | TREATMENT OF RNASE H1-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1 |
CA2790506A1 (en) | 2010-02-22 | 2011-08-25 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
CA2795145C (en) | 2010-04-02 | 2019-01-22 | Curna, Inc. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
TWI644675B (zh) | 2010-04-09 | 2018-12-21 | 可娜公司 | 藉由抑制纖維母細胞生長因子21(fgf21)之天然反義轉錄物以治療fgf21相關疾病 |
KR20130101442A (ko) | 2010-05-03 | 2013-09-13 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료 |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
RU2620978C2 (ru) | 2010-05-26 | 2017-05-30 | Курна, Инк. | Лечение заболеваний, связанных с метионинсульфоксидредуктазой а (msra), путем ингибирования природного антисмыслового транскрипта гена msra |
JP5973996B2 (ja) | 2010-05-26 | 2016-08-23 | カッパーアールエヌエー,インコーポレイテッド | Atoh1に対する天然アンチセンス転写物の阻害による無調ホモログ1(atoh1)関連疾患の治療 |
WO2011150241A2 (en) | 2010-05-28 | 2011-12-01 | Genentech, Inc. | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
RU2016118528A (ru) | 2010-06-23 | 2018-10-31 | Курна, Инк. | Лечение заболеваний, связанных с альфа-субъединицей потенциалзависимого натриевого канала (scna), путем ингибирования природного антисмыслового транскрипта гена scna |
RU2611190C2 (ru) | 2010-07-14 | 2017-02-21 | Курна, Инк. | Лечение заболеваний, связанных с геном dlg, путем ингибирования природного антисмыслового транскрипта гена dlg |
US20120083035A1 (en) | 2010-09-30 | 2012-04-05 | Dharmacon, Inc. | Modified Cell Lines for Increasing Lentiviral Titers |
US8993533B2 (en) | 2010-10-06 | 2015-03-31 | Curna, Inc. | Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 |
US9222088B2 (en) | 2010-10-22 | 2015-12-29 | Curna, Inc. | Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA |
US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
KR102010598B1 (ko) | 2010-11-23 | 2019-08-13 | 큐알엔에이, 인크. | Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료 |
US9631002B2 (en) | 2010-12-21 | 2017-04-25 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin K-dependent proteins |
RU2013131825A (ru) | 2011-01-10 | 2015-02-20 | Зе Реджентс Оф Зе Юниверсити Оф Мичиган | Ингибитор фактора стволовых клеток |
US20150018408A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
CN103620036B (zh) | 2011-06-09 | 2016-12-21 | 库尔纳公司 | 通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病 |
WO2013001372A2 (en) | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
US10980879B2 (en) | 2011-07-06 | 2021-04-20 | Sykehuset Sørlandet Hf | EGFR targeted therapy |
EA029151B1 (ru) | 2011-09-06 | 2018-02-28 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ |
HUE040179T2 (hu) | 2012-03-15 | 2019-02-28 | Curna Inc | Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén |
US9695443B2 (en) * | 2012-05-25 | 2017-07-04 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Vector for the selective silencing of a gene in astrocytes |
PT2800811T (pt) | 2012-05-25 | 2017-08-17 | Univ California | Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição |
ES2769310T3 (es) | 2012-12-06 | 2020-06-25 | Sigma Aldrich Co Llc | Modificación y regulación del genoma basada en CRISPR |
MX2015007550A (es) | 2012-12-12 | 2017-02-02 | Broad Inst Inc | Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas. |
EP2931892B1 (en) | 2012-12-12 | 2018-09-12 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
AU2013362134B2 (en) | 2012-12-21 | 2018-07-05 | Sykehuset Sorlandet Hf | EGFR targeted therapy of neurological disorders and pain |
AU2014281026B2 (en) | 2013-06-17 | 2020-05-28 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
EP3011034B1 (en) | 2013-06-17 | 2019-08-07 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
RU2716420C2 (ru) | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени |
WO2014204727A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
CN105492611A (zh) | 2013-06-17 | 2016-04-13 | 布罗德研究所有限公司 | 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物 |
MX2016007328A (es) | 2013-12-12 | 2017-07-19 | Broad Inst Inc | Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma. |
WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
AU2014362248A1 (en) | 2013-12-12 | 2016-06-16 | Massachusetts Institute Of Technology | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
KR102228828B1 (ko) | 2014-03-11 | 2021-03-16 | 셀렉티스 | 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법 |
WO2015143078A1 (en) | 2014-03-18 | 2015-09-24 | University Of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
CN106460025A (zh) | 2014-03-25 | 2017-02-22 | 阿克丘勒斯治疗公司 | 在基因沉默中具有降低的脱靶效应的una寡聚物 |
WO2015148582A1 (en) | 2014-03-25 | 2015-10-01 | Arcturus Therapeutics, Inc. | Transthyretin allele selective una oligomers for gene silencing |
US9856475B2 (en) | 2014-03-25 | 2018-01-02 | Arcturus Therapeutics, Inc. | Formulations for treating amyloidosis |
EP4299126A3 (en) | 2014-06-26 | 2024-04-03 | The Johns Hopkins University | Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
MX2017006216A (es) | 2014-11-14 | 2018-08-29 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). |
EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
US10519447B2 (en) | 2015-04-01 | 2019-12-31 | Arcturus Therapeutics, Inc. | Therapeutic UNA oligomers and uses thereof |
RU2752834C2 (ru) | 2015-06-18 | 2021-08-09 | Те Брод Инститьют, Инк. | Мутации фермента crispr, уменьшающие нецелевые эффекты |
WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
WO2017015671A1 (en) | 2015-07-23 | 2017-01-26 | Arcturus Therapeutics, Inc. | Compositions for treating amyloidosis |
ES2844899T3 (es) | 2015-12-10 | 2021-07-23 | Fibrogen Inc | Métodos para el tratamiento de enfermedades de las neuronas motoras |
KR101965379B1 (ko) * | 2016-04-29 | 2019-04-03 | 이화여자대학교 산학협력단 | 유전자 침묵효과가 강화된 다이서 기질로서의 rna 나노구조체 및 이의 제조 방법 |
CN109831916B (zh) | 2016-05-18 | 2023-07-21 | 沃雅戈治疗公司 | 治疗亨廷顿氏舞蹈病的组合物和方法 |
IL302748A (en) | 2016-05-18 | 2023-07-01 | Voyager Therapeutics Inc | modulatory polynucleotides |
EP3519582A1 (en) | 2016-07-29 | 2019-08-07 | Danmarks Tekniske Universitet | Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides |
US10457940B2 (en) * | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
BR112019012312A8 (pt) | 2016-12-14 | 2023-02-28 | Benitec Biopharma Ltd | Reagentes para tratamento da distrofia muscular oculofaríngea (opmd) e uso dos mesmos |
AU2018212986A1 (en) | 2017-01-28 | 2019-08-08 | Inari Agriculture Technology, Inc. | Novel plant cells, plants, and seeds |
CN110770343A (zh) * | 2017-02-10 | 2020-02-07 | 成均馆大学校产学协力团 | 用于rna干扰的长双链rna |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
CN110913866A (zh) | 2017-05-05 | 2020-03-24 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
WO2018208972A1 (en) | 2017-05-09 | 2018-11-15 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (als) |
JP7397488B2 (ja) | 2017-09-22 | 2023-12-13 | ユニバーシティ オブ マサチューセッツ | Sod1二重発現ベクターおよびその使用 |
US11603536B2 (en) | 2017-09-29 | 2023-03-14 | Inari Agriculture Technology, Inc. | Methods for efficient maize genome editing |
US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
JP7502991B2 (ja) | 2017-10-16 | 2024-06-19 | ボイジャー セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症(als)の治療 |
US11926835B1 (en) | 2018-01-29 | 2024-03-12 | Inari Agriculture Technology, Inc. | Methods for efficient tomato genome editing |
US11802288B1 (en) | 2018-01-29 | 2023-10-31 | Inari Agriculture Technology, Inc. | Methods for efficient soybean genome editing |
US11220694B1 (en) | 2018-01-29 | 2022-01-11 | Inari Agriculture, Inc. | Rice cells and rice plants |
RU2020125769A (ru) | 2018-02-09 | 2022-03-10 | Дженентек, Инк. | Олигонуклеотиды для модуляции экспрессии tmem106b |
WO2019215067A1 (en) | 2018-05-07 | 2019-11-14 | Roche Innovation Center Copenhagen A/S | Massively parallel discovery methods for oligonucleotide therapeutics |
US11866719B1 (en) | 2018-06-04 | 2024-01-09 | Inari Agriculture Technology, Inc. | Heterologous integration of regulatory elements to alter gene expression in wheat cells and wheat plants |
MX2021001056A (es) | 2018-08-13 | 2021-04-12 | Alnylam Pharmaceuticals Inc | Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas. |
US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
EP4288440A1 (en) | 2021-02-02 | 2023-12-13 | The Johns Hopkins University | Peripherally restricted gaba positive allosteric modulators |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5208149A (en) * | 1983-10-20 | 1993-05-04 | The Research Foundation Of State University Of New York | Nucleic acid constructs containing stable stem and loop structures |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
ATE68013T1 (de) | 1985-07-05 | 1991-10-15 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
JP2627899B2 (ja) | 1987-08-19 | 1997-07-09 | 株式会社 ビタミン研究所 | 遺伝子封入リポソームの製法 |
US5175385A (en) | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
US5252726A (en) | 1987-09-04 | 1993-10-12 | Novo Nordisk A/S | Promoters for use in aspergillus |
ATE117375T1 (de) | 1987-09-11 | 1995-02-15 | Whitehead Biomedical Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
DE3851153T2 (de) | 1987-12-11 | 1995-01-05 | Hughes Howard Med Inst | Genetische modifizierung von endothelialen zellen. |
DE68927996T2 (de) | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | Modifizierte hepatozyten und deren anwendung |
US5070020A (en) | 1988-05-09 | 1991-12-03 | Eli Lilly And Company | Recombinant dna expression vectors and dna compounds that encode deacetoxycephalosporin c synthetase |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5175383A (en) | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
WO1991006556A1 (en) * | 1989-10-24 | 1991-05-16 | Gilead Sciences, Inc. | 2' modified oligonucleotides |
DK0452457T3 (da) | 1989-11-03 | 1998-03-02 | Univ Vanderbilt | Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener |
US6946587B1 (en) | 1990-01-22 | 2005-09-20 | Dekalb Genetics Corporation | Method for preparing fertile transgenic corn plants |
US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
ATE163046T1 (de) | 1990-10-31 | 1998-02-15 | Somatix Therapy Corp | Genetische veränderung von endothelzellen |
WO1994008003A1 (en) * | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
US6117847A (en) * | 1992-03-16 | 2000-09-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides for enhanced modulation of protein kinase C expression |
US5792751A (en) | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
US5693535A (en) | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
AU4770093A (en) | 1992-07-02 | 1994-01-31 | Hybridon, Inc. | Self-stabilized oligonucleotides as therapeutic agents |
US5808036A (en) * | 1993-09-01 | 1998-09-15 | Research Corporation Technologies Inc. | Stem-loop oligonucleotides containing parallel and antiparallel binding domains |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
DE4421079C1 (de) * | 1994-06-16 | 1995-08-17 | Peter Dr Rer Nat Seibel | Chimäres Peptid-Nukleinsäure-Fragment, Verfahren zu seiner Herstellung und die Verwendung des Fragments zur zielgerichteten Nukleinsäureeinbringung in Zellorganellen und Zellen |
US6057153A (en) * | 1995-01-13 | 2000-05-02 | Yale University | Stabilized external guide sequences |
US5631146A (en) * | 1995-01-19 | 1997-05-20 | The General Hospital Corporation | DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof |
WO1996029097A1 (en) * | 1995-03-21 | 1996-09-26 | Research Corporation Technologies, Inc. | Stem-loop and circular oligonucleotides |
US5674683A (en) * | 1995-03-21 | 1997-10-07 | Research Corporation Technologies, Inc. | Stem-loop and circular oligonucleotides and method of using |
GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US6022863A (en) | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
ES2150832B1 (es) | 1996-06-12 | 2001-06-16 | Fichtel & Sachs Ag | Dispositivo de maniobra para la maniobra, en particular maniobra neumatica, de un embrague de friccion. |
US20030064945A1 (en) * | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
GB9703146D0 (en) * | 1997-02-14 | 1997-04-02 | Innes John Centre Innov Ltd | Methods and means for gene silencing in transgenic plants |
GB9710475D0 (en) | 1997-05-21 | 1997-07-16 | Zeneca Ltd | Gene silencing |
US6183959B1 (en) * | 1997-07-03 | 2001-02-06 | Ribozyme Pharmaceuticals, Inc. | Method for target site selection and discovery |
EP2341058A3 (en) | 1997-09-12 | 2011-11-23 | Exiqon A/S | Oligonucleotide Analogues |
GB9720148D0 (en) | 1997-09-22 | 1997-11-26 | Innes John Centre Innov Ltd | Gene silencing materials and methods |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
ATE526406T1 (de) * | 1998-03-20 | 2011-10-15 | Commw Scient Ind Res Org | Kontrolle der genexpression |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
CN1202246C (zh) | 1998-04-08 | 2005-05-18 | 联邦科学和工业研究组织 | 获得修饰表型的方法和措施 |
AR020078A1 (es) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
KR20010079671A (ko) | 1998-08-20 | 2001-08-22 | 스티븐 에이. 서윈. 엠.디. | 재조합 유전자 생성물을 생성시키는 동안 세포독성을조절하는 억제 tRNA의 용도 |
IT1302708B1 (it) | 1998-10-20 | 2000-09-29 | Unifor Spa | Contenitore di immagazzinaggio con porta controbilanciata |
EP1050583A4 (en) | 1998-11-24 | 2005-02-02 | Hisamitsu Pharmaceutical Co | INHIBITORS OF HIV INFECTIONS |
US6939712B1 (en) * | 1998-12-29 | 2005-09-06 | Impedagen, Llc | Muting gene activity using a transgenic nucleic acid |
EP1147204A1 (en) * | 1999-01-28 | 2001-10-24 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
WO2000049035A1 (en) | 1999-02-19 | 2000-08-24 | The General Hospital Corporation | Gene silencing |
GB9904905D0 (en) | 1999-03-03 | 1999-04-28 | Oxford Biomedica Ltd | Cells |
FR2790757B1 (fr) | 1999-03-09 | 2003-08-01 | Bioalliance Pharma | Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant. |
WO2000063364A2 (en) | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
US6423885B1 (en) * | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
WO2001012789A2 (en) * | 1999-08-18 | 2001-02-22 | Baylor College Of Medicine | APOLIPOPROTEIN B mRNA-SPECIFIC RIBOZYME |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
RU2164944C1 (ru) | 1999-12-09 | 2001-04-10 | Институт молекулярной биологии им. В.А. Энгельгардта РАН | Способ изменения генетических свойств организма |
WO2001049844A1 (en) | 1999-12-30 | 2001-07-12 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
EP1272630A2 (en) * | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
US20030084471A1 (en) | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
US8202846B2 (en) | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
AU2001240375A1 (en) | 2000-03-17 | 2001-10-03 | Benitec Australia Limited | Genetic silencing |
AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
US6506099B1 (en) | 2000-04-05 | 2003-01-14 | Applied Materials, Inc. | Driving a carrier head in a wafer polishing system |
WO2001092513A1 (en) | 2000-05-30 | 2001-12-06 | Johnson & Johnson Research Pty Limited | METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi |
HU230458B1 (hu) * | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Az RNS interferenciát közvetítő kis RNS molekulák |
NZ526194A (en) | 2000-12-08 | 2004-10-29 | Invitrogen Corp | Methods of covalently linking, in one or both strands, two or more double stranded nucleotide sequences using one or more topoisomerases |
JP2004532616A (ja) | 2000-12-28 | 2004-10-28 | ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド | 二本鎖rna仲介遺伝子抑制 |
CA2369944A1 (en) | 2001-01-31 | 2002-07-31 | Nucleonics Inc. | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
US20040010130A1 (en) | 2001-02-22 | 2004-01-15 | Motoya Katsuki | Recombinant gene containing inverted repeat sequence and utilization thereof |
GB0104948D0 (en) | 2001-02-28 | 2001-04-18 | Novartis Res Foundation | Novel methods |
ES2566561T3 (es) * | 2001-07-12 | 2016-04-13 | University Of Massachusetts | Producción in vivo de ARN pequeños de interferencia que median el silenciamiento génico |
US10590418B2 (en) * | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
GB0118223D0 (en) | 2001-07-26 | 2001-09-19 | Univ Sheffield | Stem loop RNA |
US20030198627A1 (en) * | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
EP2385123B1 (en) * | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
DE10230997A1 (de) | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
US20030148519A1 (en) * | 2001-11-14 | 2003-08-07 | Engelke David R. | Intracellular expression and delivery of siRNAs in mammalian cells |
WO2003046173A1 (fr) * | 2001-11-28 | 2003-06-05 | Center For Advanced Science And Technology Incubation, Ltd. | Systeme d'expression d'arn si et procede de production de cellules d'inactivation de genes fonctionnelles et analogues au moyen de ce systeme |
JP3642573B2 (ja) | 2001-11-28 | 2005-04-27 | 株式会社東京大学Tlo | siRNA発現システムおよびこれを用いた機能遺伝子ノックダウン細胞等の生産方法 |
DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
US20030166282A1 (en) | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
US20030180756A1 (en) * | 2002-03-21 | 2003-09-25 | Yang Shi | Compositions and methods for suppressing eukaryotic gene expression |
AU2003265978A1 (en) * | 2002-05-03 | 2003-11-17 | Duke University | A method of regulating gene expression |
AU2002951347A0 (en) | 2002-09-09 | 2002-09-26 | Benitec Australia Ltd | Genetic silencing |
JP2005026805A (ja) * | 2003-06-30 | 2005-01-27 | Renesas Technology Corp | 半導体集積回路 |
US7485468B2 (en) | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
-
2002
- 2002-07-12 ES ES02746979.0T patent/ES2566561T3/es not_active Expired - Lifetime
- 2002-07-12 US US10/195,034 patent/US7691995B2/en active Active
- 2002-07-12 CA CA2921821A patent/CA2921821A1/en not_active Abandoned
- 2002-07-12 BR BR0211111-0A patent/BR0211111A/pt not_active IP Right Cessation
- 2002-07-12 KR KR10-2004-7000474A patent/KR20040022449A/ko active Search and Examination
- 2002-07-12 IL IL15975602A patent/IL159756A0/xx active IP Right Grant
- 2002-07-12 EP EP02746979.0A patent/EP1412371B1/en not_active Expired - Lifetime
- 2002-07-12 ES ES10183024.8T patent/ES2609014T3/es not_active Expired - Lifetime
- 2002-07-12 ES ES07023866.2T patent/ES2606290T3/es not_active Expired - Lifetime
- 2002-07-12 WO PCT/US2002/022010 patent/WO2003006477A1/en active Application Filing
- 2002-07-12 EP EP10183024.8A patent/EP2360251B1/en not_active Expired - Lifetime
- 2002-07-12 EP EP10183026A patent/EP2345720A3/en not_active Withdrawn
- 2002-07-12 CA CA2453183A patent/CA2453183C/en not_active Expired - Lifetime
- 2002-07-12 JP JP2003512247A patent/JP4210737B2/ja not_active Expired - Lifetime
- 2002-07-12 KR KR1020097006537A patent/KR101021695B1/ko active IP Right Grant
-
2004
- 2004-01-07 IL IL159756A patent/IL159756A/en active IP Right Review Request
-
2008
- 2008-03-26 US US12/079,531 patent/US7893036B2/en not_active Expired - Lifetime
-
2010
- 2010-03-19 US US12/727,783 patent/US8530438B2/en not_active Expired - Lifetime
- 2010-03-23 US US12/729,360 patent/US8557785B2/en not_active Expired - Lifetime
- 2010-04-15 IL IL205128A patent/IL205128A/en active IP Right Grant
-
2011
- 2011-02-21 US US13/031,522 patent/US8232260B2/en not_active Expired - Lifetime
-
2013
- 2013-09-09 US US14/021,845 patent/US9175287B2/en not_active Expired - Lifetime
-
2015
- 2015-09-15 US US14/854,878 patent/US9850487B2/en not_active Expired - Lifetime
-
2017
- 2017-11-15 US US15/814,353 patent/US10731155B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0211111A (pt) | Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula | |
ES2253565T3 (es) | Metodo para la sintesis in vitro de arns cortos de doble cadena. | |
CY1120292T1 (el) | ΔΙΑΜΕΣΟΛΑΒΟΥΜΕΝΗ ΑΠΟ RNA ΠΑΡΕΜΒΟΛΗ ΑΝΑΣΤΟΛΗ ΤΗΣ ΓΟΝΙΔΙΑΚΗΣ ΕΚΦΡΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΒΡΑΧΥ ΠΑΡΕΜΒΑΛΛΟΜΕΝΟ ΝΟΥΚΛΕΪΚΟ ΟΞΥ (siNA) | |
Su et al. | Natural antisense transcripts regulate gene expression in an epigenetic manner | |
Ferino et al. | MicroRNA therapeutics: design of single-stranded miR-216b mimics to target KRAS in pancreatic cancer cells | |
Murata et al. | Xanthone derivatives as potential inhibitors of miRNA processing by human Dicer: targeting secondary structures of pre-miRNA by small molecules | |
WO2007095387A8 (en) | Compositions and methods for inhibiting gene silencing by rna interference | |
WO2004011624A3 (en) | Double stranded rna structures and constructs, and methods for generating and using the same | |
Elia et al. | RNA (Epi) genetics in cardiovascular diseases | |
Grüll et al. | Mimicry, deception and competition: the life of competing endogenous RNAs | |
Østergaard et al. | Allele-selective inhibition of mutant Huntingtin with 2-thio-and C5-triazolylphenyl-deoxythymidine-modified antisense oligonucleotides | |
Fiszer et al. | Silencing of genes responsible for polyQ diseases using chemically modified single-stranded siRNAs | |
Prashad | miR-665 targets c-MYC and HDAC8 to inhibit murine neuroblastoma cell growth | |
US5821052A (en) | Control of the synthesis of proteins by anitisense RNA-tRNA complex | |
Zhang et al. | Demethyltransferase AlkBH1 substrate diversity and relationship to human diseases | |
Weissenboeck et al. | Optochemical control of mRNA translation in eukaryotes | |
Dmochowski et al. | Taking control of gene expression with light-activated oligonucleotides | |
Prakash et al. | RNA interference by 2′, 5′-linked nucleic acid duplexes in mammalian cells | |
Luo et al. | Synthesis of oligonucleotides with glucosamine at the 3′-position and evaluation of their biological activity | |
WO2009083253A1 (en) | Positive controls for expression modulating experiments | |
Sano et al. | Expanding the utility of heptamer-type sgRNA for TRUE gene silencing | |
Gorska et al. | Modulation of p53 expression using antisense oligonucleotides complementary to the 5′-terminal region of p53 mRNA in vitro and in the living cells | |
Woudenberg et al. | Change of heart: the epitranscriptome of small non-coding RNAs in heart failure | |
Kajino et al. | (S)-5′-C-Aminopropyl-2′-O-methyl nucleosides enhance antisense activity in cultured cells and binding affinity to complementary single-stranded RNA | |
EP1900815A3 (en) | In vivo production of small interfering RNAs that mediate gene silencing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A,5A,6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |